Amitrid may be available in the countries listed below.
Amiloride hydrochloride dihydrate (a derivative of Amiloride) is reported as an ingredient of Amitrid in the following countries:
Hydrochlorothiazide is reported as an ingredient of Amitrid in the following countries:
International Drug Name Search
Carboplatino Martian may be available in the countries listed below.
Carboplatin is reported as an ingredient of Carboplatino Martian in the following countries:
International Drug Name Search
Leo may be available in the countries listed below.
Levofloxacin is reported as an ingredient of Leo in the following countries:
International Drug Name Search
Ketocev may be available in the countries listed below.
Ketotifen fumarate (a derivative of Ketotifen) is reported as an ingredient of Ketocev in the following countries:
International Drug Name Search
Saldoren may be available in the countries listed below.
Pentazocine is reported as an ingredient of Saldoren in the following countries:
International Drug Name Search
Taro-Amcinonide may be available in the countries listed below.
Amcinonide is reported as an ingredient of Taro-Amcinonide in the following countries:
International Drug Name Search
Vasaprostan may be available in the countries listed below.
Alprostadil is reported as an ingredient of Vasaprostan in the following countries:
International Drug Name Search
Sulidene may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Nimesulide is reported as an ingredient of Sulidene in the following countries:
International Drug Name Search
Somol may be available in the countries listed below.
Diphenhydramine hydrochloride (a derivative of Diphenhydramine) is reported as an ingredient of Somol in the following countries:
International Drug Name Search
Generic Name: Prednicarbate
Class: Anti-inflammatory Agents
ATC Class: D07AC18
VA Class: DE200
Chemical Name: (11β)-17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-pregna-1,4-diene-3,20-dione
Molecular Formula: C27H36O8
CAS Number: 73771-04-7
A synthetic corticosteroid.1 2 3 11
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.1 2 3 4 11
Generally most effective in acute or chronic dermatoses (e.g., seborrheic or atopic dermatitis, localized neurodermatitis, anogenital pruritus, psoriasis, late phase of allergic contact dermatitis, inflammatory phase of xerosis).b
Topical therapy generally preferred over systemic therapy; fewer associated adverse systemic effects.b
Topical therapy generally only controls manifestations of dermatoses; eliminate cause if possible.b
Topical efficacy may be increased by using a higher concentration or occlusive dressing therapy. (See Administration with Occlusive Dressing under Dosage and Administration.)b
Response may vary from one topical corticosteroid preparation to another.b
Anti-inflammatory activity may vary considerably depending on the vehicle, drug concentration, site of application, disease, and individual patient.b
Prednicarbate 0.1% ointment and 0.1% cream are considered to have medium-range potency.1 c
Consider location of the lesion and the condition being treated when choosing a dosage form.b
Creams are suitable for most dermatoses, but ointments may also provide some occlusion and are usually used for the treatment of dry, scaly lesions.b
Formulation affects percutaneous penetration and subsequent activity; extemporaneous preparation or dilution of commercially available products with another vehicle may decrease effectiveness.b
Patients applying a topical corticosteroid to a large surface area and/or to areas under occlusion should be evaluated periodically for evidence of hypothalamic-pituitary-adrenal (HPA)-axis suppression by appropriate endocrine testing (e.g., ACTH stimulation, plasma cortisol, urinary free cortisol).b (See Hypothalamic-Pituitary-Adrenal Axis Suppression and also Systemic Effects, under Cautions.)
For dermatologic use only; avoid contact with eyes.1 c
Apply creams and ointments topically to the skin or scalp.1 c
The area of skin to be treated may be thoroughly cleansed before topical application to reduce the risk of infection; however, some clinicians believe that, unless an occlusive dressing is used, cleansing of the treated area is unnecessary and may be irritating.b
Apply cream or ointment sparingly in a thin film and rub gently into the affected area.1 c
After a favorable response is achieved, frequency of application or concentration (strength) may be decreased to the minimum necessary to maintain control and to avoid relapse; discontinue if possible.b
Occlusive dressings may be used for severe or resistant dermatoses.1 3 11 (See Occlusive Dressings under Cautions.)
Soak or wash the affected area to remove scales; apply a thin film of cream or ointment; rub gently into the lesion; and apply another thin film.b Cover affected area with a thin, pliable plastic film and seal it to adjacent normal skin with adhesive tape or hold in place with a gauze or elastic bandage.b
If affected area is moist, incompletely seal the edges of the plastic film or puncture the film to allow excess moisture to escape.b For added moisture in dry lesions, apply cream or ointment and cover with a dampened cloth before the plastic film is applied or briefly soak the affected area in water before application of the drug and plastic film.b
Thin polyethylene gloves may be used on the hands and fingers, plastic garment bags may be used on the trunk or buttocks, a tight shower cap may be used for the scalp, or whole-body suits may be used instead of plastic film to provide occlusion.b
Frequency of occlusive dressing changes depends on the condition being treated; cleansing of the skin and reapplication of the corticosteroid are essential at each dressing change.b
Occlusive dressing is usually left in place for 12–24 hours and therapy is repeated as needed.b Although occlusive dressing may be left in place for 3–4 days at a time in resistant conditions, most clinicians recommend intermittent use of occlusive dressings for 12 hours daily to reduce the risk of adverse effects (particularly infection) and systemic absorption and for greater convenience.b
The drug and an occlusive dressing may be used at night, and the drug or a bland emollient may be used without an occlusive dressing during the day.b
In patients with extensive lesions, sequential occlusion of only one portion of the body at a time may be preferable to whole-body occlusion.b (See Occlusive Dressings under Cautions.)
Administer the least amount of topical preparations that provide effective therapy.b (See Pediatric Use under Cautions.)
Children ≥1 year of age: Apply cream sparingly twice daily.1
Children ≥10 years of age: Apply ointment sparingly twice daily.11
Discontinue when control is achieved; if improvement does not occur within 2 weeks, consider reassessment of the diagnosis.1
Apply cream or ointment sparingly twice daily.1 3 4 11
Discontinue when control is achieved; if improvement does not occur within 2 weeks, consider reassessment of the diagnosis.1
Children ≥ 1 year of age: Maximum 3 weeks.1
No special population dosage recommendations at this time.1 c
Known hypersensitivity to prednicarbate or any ingredient in the formulation.1 c
Allergic contact dermatitis may manifest as failure to heal rather than irritation as occurs with other topical preparations that do not contain corticosteroids; confirm with diagnostic patch testing.1 b c
Topically applied corticosteroids can be absorbed in sufficient amounts to reversibly suppress the HPA axis.1 b c
Perform periodic HPA-axis evaluation by appropriate testing (e.g., ACTH stimulation, morning plasma cortisol, urinary free cortisol), especially in patients applying a topical corticosteroid to a large surface area or to areas under occlusion.1 b c
If HPA-axis suppression occurs, withdraw the drug, reduce the frequency of application, and/or substitute a less potent corticosteroid.1 b c
HPA-axis function recovery generally is prompt and complete following drug discontinuance.1 b c
Rarely, glucocorticosteroid insufficiency may require systemic corticosteroid therapy.1 b c
Systemic absorption following topical administration may result in manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.1 b c
Adverse systemic effects may occur when corticosteroids are used on large areas of the body, for prolonged periods of time, with an occlusive dressing, and/or concurrently with other corticosteroid-containing preparations.b
Infants and children may be more susceptible to adverse systemic effects.1 b c (See Pediatric Use under Cautions.)
Possible adverse local reactions (e.g., burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria); may occur more frequently with the use of occlusive dressings, especially with prolonged therapy.1 b c
Prolonged use of topical corticosteroids may cause atrophy of the epidermis and subcutaneous tissue;b these effects are most likely to occur (even with short-term use) in intertriginous (e.g., axilla, groin), flexor, and facial areas.b
If irritation occurs, discontinue drug and institute appropriate therapy.1 b c
If concurrent skin infection is present or develops, initiate appropriate anti-infective therapy.1 b c If infection does not respond promptly, discontinue topical corticosteroid therapy until the infection has been controlled.1 b c
When topical corticosteroids and topical anti-infectives are used concomitantly, consider that the corticosteroid may mask clinical signs of bacterial, fungal, or viral infections; prevent recognition of ineffectiveness of the anti-infective; or suppress hypersensitivity reactions to ingredients in the formulation.b In addition, consider the cautions, precautions, and contraindications associated with the anti-infective.b (See Occlusive Dressings under Cautions.)
Some manufacturers state that topical corticosteroids are contraindicated in patients with tuberculosis of the skin, dermatologic fungal infections, and cutaneous or systemic viral infection (including vaccinia and varicella and herpes simplex of the eye or adjacent skin).b However, most clinicians believe topical corticosteroids can be used with caution if the infection is treated.b
Adverse systemic corticosteroid effects may occur with use of occlusive dressings on large areas of the body and for prolonged periods of time; monitor accordingly.b (See Hypothalamic-Pituitary-Adrenal Axis Suppression and also Systemic Effects, under Cautions.)
Adverse local reactions may occur more frequently with the use of occlusive dressings, especially with prolonged therapy.1 b c (See Local Effects under Cautions.)
Do not use occlusive dressings on weeping or exudative lesions.b
Do not use occlusive dressings in patients with primary skin infection.b
Remove occlusive dressings covering large areas if body temperature increases; thermal homeostasis may be impaired.b
Use plastic occlusive material with care to avoid the risk of suffocation.b
Category C.1 c
Not known whether topical prednicarbate is distributed into milk.1 c Caution advised if topical prednicarbate is used.1 c
Safety and efficacy of prednicarbate cream not established in children <1 year of age.1 In children ≥1 year of age, safety and efficacy of cream for >3 weeks not established.1
Safety and efficacy of prednicarbate ointment not established in children <10 years of age.c
Do not use cream to treat diaper dermatitis.1 Tight-fitting diapers or plastic pants may constitute occlusive dressings.1 b
Children are more susceptible to topical corticosteroid-induced HPA-axis suppression and Cushing's syndrome than mature individuals because of a greater skin surface area-to-body weight ratio,1 b c especially when topical corticosteroids are applied to >20% of body surface area.1 The risk of adrenal suppression appears to increase with decreasing age.b (See Systemic Effects under Cautions.)
Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol concentrations, and lack of response to corticotropin (ACTH) stimulation.1 b c
Children also are at greater risk of glucocorticoid insufficiency during and/or after withdrawal of treatment.1 c
Intracranial hypertension has occurred in children; manifestations include bulging fontanelles, headaches, and bilateral papilledema.1 b c
Topical corticosteroid therapy in children should be limited to the minimum amount necessary for therapeutic efficacy; chronic topical corticosteroid therapy may interfere with growth and development.b
Burning, itching, drying, scaling, cracking, pain, irritant dermatitis,c mild atrophy, telangiectasia,1 folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria.c
Drug or Test | Interaction |
|---|---|
Nitroblue-tetrazolium test for bacterial infection | Concurrent use of corticosteroids reportedly may result in false-negative resultsb |
Topically applied prednicarbate can be absorbed through normal intact skin.1 b c
Percutaneous penetration of corticosteroids following topical application to the skin varies among individuals and may be increased by occlusive dressings, high corticosteroid concentrations, and certain vehicles.b
Only minimal amounts of topical corticosteroid reach the dermis and subsequently the systemic circulation after application to most normal skin areas; more absorption occurs from the scrotum, axilla, eyelid, face, and scalp than from the forearm, knee, elbow, palm, and sole.b
Absorption is markedly increased by loss of the skin’s keratin layer and by inflammation and/or diseases of the epidermal barrier (e.g., psoriasis, eczema).1 b c
Not known whether topical prednicarbate is distributed into milk.1 b c
Once absorbed through the skin, topically applied corticosteroids are metabolized primarily in the liver.b
Topical corticosteroids and metabolites are excreted by the kidneys and, to a lesser extent, in bile.b
5–25°C.1
15–30°C.c
Medium-range corticosteroid activity.1 c
Precise mechanism of action for topical anti-inflammatory activity is unknown; therapeutic benefit in the management of corticosteroid-responsive dermatoses mediated primarily through anti-inflammatory, antipruritic, and vasoconstrictive actions.1 b c
Anti-inflammatory effects may occur through induction of phospholipase A2 inhibitory proteins (lipocortins); decreased arachidonic acid release from membrane phospholipids.1 c Decreased arachidonic acid precursors may downregulate biosynthesis of potent inflammatory mediators (e.g., prostaglandins, leukotrienes).1 c
Decreases inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates; reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation; and possibly by other mechanisms as yet unknown.b
Importance of using only as directed, only for the disorder for which it was prescribed, and for no longer than prescribed; avoid contact with the eyes and only apply externally as directed.1 c (See Topical Administration under Dosage and Administration.)
Importance of not using cream on the face, underarms, or groin areas.1
Importance of informing patients that treated areas of the skin should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by a clinician.1 c
Importance of reporting any local adverse reactions, especially those occurring under occlusive bandage, to a clinician.b 1 c
Importance of informing parents of children that cream should not be used for diaper dermatitis or applied in the diaper area as diapers or plastic pants may constitute occlusive dressing.1
Advise patient to discontinue medication when control is achieved; if no improvement is seen in 2 weeks, contact clinician.1
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs; other corticosteroid-containing preparations should not be used without first consulting with clinician.1 c
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1 c
Importance of advising patients of other important precautionary information. (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Topical | Cream | 0.1% | Dermatop Emollient | Dermik |
Ointment | 0.1% | Dermatop | Dermik |
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions January 2008. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
1. Dermik Laboratories. Dermatop (prednicarbate) emollient cream 0.1% prescribing information. Berwyn, PA; 2003 May.
2. Schäfer-Korting M, Korting HC, Kerscher MJ et al. Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids. Clin Pharmacol Ther. 1993; 54:448-56. [IDIS 321791] [PubMed 8222488]
3. Hoechst-Roussel Dermatology. Dermatop (prednicarbate) emollient cream 0.1% product monograph. Somerville, NJ; 1993 Jul.
4. Hanifin J, Abrams BB, Cherill RJ. Management of atopic dermatitis with prednicarbate emollient cream 0.1%, a nonhalogenated prednisolone derivative. J Geriatr Dermatol. 1994; 2:119-27.
5. Cornell RC, Cherill RJ, Abrams BB. Safety of prednicarbate emollient cream 0.1% and ointment 0.1%, nonhalogenated, midpotency topical steroid formulations. J Geriatr Dermatol. 1994; 2:57-65.
6. Korting HC, Vieluf D, Kerscher M. 0.25% Prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream. Eur J Clin Pharmacol. 1992; 42:159-61. [IDIS 293468] [PubMed 1618247]
7. Korting HC, Kerscher MJ, Schäfer-Korting M. Topical glucorticoids with improved benefit/risk ratio: do they exist? J Am Acad Dermatol. 1992; 27:87-92.
8. Hoechst-Roussel Dermatology, Somerville, NJ: Personal communication.
9. Hein R, Korting HC, Mehring T. Differential effect of medium potent nonhalogenated double-ester-type and conventional glucocorticoids on proliferation and chemotaxis of fibroblasts in vitro. Skin Pharmacol. 1994; 7:300-6. [PubMed 8054213]
10. Levy J, Gassmuller J, Schroder G et al. Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness. Skin Pharmacol. 1994; 7:231-6. [PubMed 8024805]
11. Dermik Laboratories. Dermatop (prednicarbate) ointment 0.1% prescribing information. Berwyn, PA; 2003 Apr.
a. AHFS drug information 2007. McEvoy GK, ed. Prednicarbate emollient. Bethesda, MD: American Society of Health-Systems Pharmacists; 2007:3535.
b. AHFS drug information 2007 McEvoy GK, ed. Topical corticosteroids general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2007:3423–5.
c. Dermik Laboratories. Dermatop (prednicarbate) ointment 0.1% prescribing information. Bridgewater, NJ; 2006 July.
Stalcare may be available in the countries listed below.
Domperidone is reported as an ingredient of Stalcare in the following countries:
International Drug Name Search
Levogastrol may be available in the countries listed below.
Levosulpiride is reported as an ingredient of Levogastrol in the following countries:
International Drug Name Search
Triantel may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Praziquantel is reported as an ingredient of Triantel in the following countries:
Pyrantel embonate (a derivative of Pyrantel) is reported as an ingredient of Triantel in the following countries:
International Drug Name Search
Amoxibol may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Amoxibol in the following countries:
International Drug Name Search
Metronidazol Ovulos may be available in the countries listed below.
Metronidazole is reported as an ingredient of Metronidazol Ovulos in the following countries:
International Drug Name Search
In the US, RiaSTAP (fibrinogen systemic) is a member of the drug class miscellaneous coagulation modifiers and is used to treat Congenital Fibrinogen Deficiency.
US matches:
Fibrinogen, human is reported as an ingredient of RiaSTAP in the following countries:
International Drug Name Search
Guardian may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ivermectin is reported as an ingredient of Guardian in the following countries:
Moxidectin is reported as an ingredient of Guardian in the following countries:
Praziquantel is reported as an ingredient of Guardian in the following countries:
Pyrantel embonate (a derivative of Pyrantel) is reported as an ingredient of Guardian in the following countries:
International Drug Name Search
Orphenadrine Citrate Injection is a sterile aqueous solution of orphenadrine citrate. It is intended for intravenous or intramuscular administration.
Orphenadrine citrate is the citrate salt of orphenadrine and occurs as a white, crystalline powder having a bitter taste. It is practically odorless, sparingly soluble in water and slightly soluble in alcohol. It has the following structural formula:
N,N-Dimethyl-2-[(o-methyl-α-phenylbenzyl)oxy]ethylamine Citrate (1:1).
Each mL contains: Orphenadrine Citrate 30 mg, Sodium Metabisulfite 0.91 mg, Sodium Chloride 2.9 mg, in Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid may have been used to adjust pH.
The mode of action has not been clearly identified but may be related to analgesic properties. Orphenadrine citrate possesses anticholinergic actions.
Orphenadrine citrate is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculo-skeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its analgesic properties. Orphenadrine citrate does not directly relax tense skeletal muscles in man.
Orphenadrine citrate is contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction at the bladder neck, cardiospasm (megaesophagus) and myasthenia gravis.
Orphenadrine citrate is contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.
Contains Sodium Metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
Some patients may experience transient episodes of lightheadedness, dizziness or syncope.
Orphenadrine citrate may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned accordingly.
Safe use of orphenadrine citrate has not been established with respect to adverse effects upon fetal development. Therefore, orphenadrine citrate should be used in women of childbearing potential and particularly during early pregnancy only when in the judgment of the physician the potential benefits outweigh the possible hazards.
Safety and effectiveness in children have not been established; therefore, this drug is not recommended for use in the pediatric age group.
Confusion, anxiety and tremors have been reported in few patients receiving propoxyphene and orphenadrine concomitantly. As these symptoms may be simply due to an additive effect, reduction of dosage and/or discontinuation of one or both agents is recommended in such cases.
Orphenadrine citrate should be used with caution in patients with cardiac decompensation, coronary insufficiency, cardiac arrhythmias, and tachycardia.
Safety of continuous long term therapy with orphenadrine citrate has not been established. Therefore if orphenadrine citrate is prescribed for prolonged use, periodic monitoring of blood, urine, and liver function values is recommended.
Adverse effects of orphenadrine citrate are mainly due to the mild anticholinergic action, and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include: tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilatation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of mental confusion. These adverse reactions can usually be eliminated by reduction in dosage. Very rare cases of aplastic anemia associated with the use of orphenadrine tablets have been reported. No causal relationship has been established.
Rare instances of anaphylactic reaction have been reported associated with the intramuscular injection of orphenadrine citrate.
Adults: 2 mL (60 mg) intravenously or intramuscularly - May be repeated every 12 hours. Relief may be maintained by one (100 mg) orphenadrine citrate tablet twice daily.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.
Orphenadrine Citrate Injection USP, 30 mg/mL is available in 2 mL ampules in cartons of 10.
Store at 20º-25ºC (68º-77ºF) [See USP controlled room temperature.]PROTECT FROM LIGHT. DO NOT USE IF PRECIPITATE OCCURS.
Literature revised: June 2010
Product No.: 1108-82
Mfd. by: Hikma Farmaceutica
(Portugal) S.A. 2705-906 Terrugem SNT, Portugal
Dist. by Watson Pharma, Inc.
Corona, CA 92880 USA
PRINCIPAL DISPLAY PANEL
NDC 0591-3222-47
10 x 2mL Sterile Ampules
60 mg/ 2mL
(30 mg/mL)
Orphenadrine
Citrate
Injection USP
60 mg/ 2 mL (30 mg/mL)
FOR INTRAVENOUS OR INTRAMUSCULAR USE
Watson Rx only
| ORPHENADRINE CITRATE orphenadrine citrate injection | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| ANDA | ANDA084779 | 07/08/2010 | |
| Labeler - Watson Laboratories, Inc. (023932721) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Hikma Farmaceutica | 452742943 | ANALYSIS, LABEL, MANUFACTURE, PACK | |
Relieving symptoms of an unproductive cough and mucus in the chest due to colds, flu, or hay fever. It may also be used for other conditions as determined by your doctor.
Organidin NR Liquid is an expectorant. It works by thinning mucus (phlegm) in the lungs and making it less sticky and easier to cough up. This reduces chest congestion by making coughs more productive.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Organidin NR Liquid. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Organidin NR Liquid. Tell your health care provider if you are taking any other medicines. However, no specific interactions with Organidin NR Liquid are known at this time.
Ask your health care provider if Organidin NR Liquid may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Organidin NR Liquid as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Organidin NR Liquid.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Nausea; vomiting.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Organidin NR side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Store Organidin NR Liquid at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Organidin NR Liquid out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Organidin NR Liquid. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Definition of Echinococcus: A tissue infection by the larval stage of the Echinococcus granulosus worm. This disease is common in South America, the Middle East, Asia and Africa. Sporadic cases have been reported in the us. Infection occurs after ingestion of eggs in infected dog faeces. The infection is carried to the liver where cysts form. Cysts may also form in the lungs, bone, brain, kidney, muscles and spleen.Symptoms include abdominal pain, itching, cough, haemoptysis, chest pain and fever. Treatment includes the surgical removal of cysts from the tissue. More...
The following drugs and medications are in some way related to, or used in the treatment of Echinococcus. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Medical Encyclopedia:
Anthraxiton may be available in the countries listed below.
Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Anthraxiton in the following countries:
International Drug Name Search
Auréomycine Evans may be available in the countries listed below.
Chlortetracycline hydrochloride (a derivative of Chlortetracycline) is reported as an ingredient of Auréomycine Evans in the following countries:
International Drug Name Search
Ampidog may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ampicillin trihydrate (a derivative of Ampicillin) is reported as an ingredient of Ampidog in the following countries:
International Drug Name Search
Dixi 35 may be available in the countries listed below.
Cyproterone is reported as an ingredient of Dixi 35 in the following countries:
Ethinylestradiol is reported as an ingredient of Dixi 35 in the following countries:
International Drug Name Search
Tearbalance may be available in the countries listed below.
Hyaluronic Acid sodium salt (a derivative of Hyaluronic Acid) is reported as an ingredient of Tearbalance in the following countries:
International Drug Name Search
Fragivix may be available in the countries listed below.
Benzarone is reported as an ingredient of Fragivix in the following countries:
International Drug Name Search
Evercil may be available in the countries listed below.
Phenylephrine hydrochloride (a derivative of Phenylephrine) is reported as an ingredient of Evercil in the following countries:
International Drug Name Search
Diuver may be available in the countries listed below.
Torasemide is reported as an ingredient of Diuver in the following countries:
International Drug Name Search
Hydrocortison Jenapharm may be available in the countries listed below.
Hydrocortisone is reported as an ingredient of Hydrocortison Jenapharm in the following countries:
International Drug Name Search
Carvedilol Adico may be available in the countries listed below.
Carvedilol is reported as an ingredient of Carvedilol Adico in the following countries:
International Drug Name Search
Protaminsulfat Leo may be available in the countries listed below.
Protamine Sulfate is reported as an ingredient of Protaminsulfat Leo in the following countries:
International Drug Name Search
In the US, Lyphocin (vancomycin systemic) is a member of the drug class glycopeptide antibiotics and is used to treat Bacteremia, Bacterial Endocarditis Prevention, Bacterial Infection, Bone infection, Burns - External, Endocarditis, Enterocolitis, Febrile Neutropenia, Meningitis, Methicillin-Resistant Staphylococcus Aureus Infection, Nosocomial Pneumonia, Peritonitis, Pneumonia, Prevention of Perinatal Group B Streptococcal Disease, Pseudomembranous Colitis, Sepsis, Shunt Infection, Skin Infection and Surgical Prophylaxis.
US matches:
Vancomycin hydrochloride (a derivative of Vancomycin) is reported as an ingredient of Lyphocin in the following countries:
International Drug Name Search
Summer Masodip may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Summer Masodip in the following countries:
International Drug Name Search
Somaflex may be available in the countries listed below.
Etidronic Acid disodium salt (a derivative of Etidronic Acid) is reported as an ingredient of Somaflex in the following countries:
International Drug Name Search
Dazzel may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Dimpylate is reported as an ingredient of Dazzel in the following countries:
International Drug Name Search
Metiltestosterone may be available in the countries listed below.
Metiltestosterone (DCIT) is known as Methyltestosterone in the US.
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
Feedmix Oxy may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Oxytetracycline hydrochloride (a derivative of Oxytetracycline) is reported as an ingredient of Feedmix Oxy in the following countries:
International Drug Name Search
Monocordil may be available in the countries listed below.
Isosorbide Mononitrate is reported as an ingredient of Monocordil in the following countries:
International Drug Name Search
Rec.INN
C01DX16
0065141-46-0
C8-H9-N3-O4
211
Coronary vasodilator
3-Pyridinecarboxamide, N-[2-(nitrooxy)ethyl]-
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Generic Name: interferon alfa-2b and ribavirin (in ter FEAR on AL fa 2b and RYE ba VYE rin)
Brand Names: Rebetron
Interferon alfa-2b is made from human proteins that help the body fight viral infections.
Ribavirin is an antiviral medication.
Interferon alfa-2b and ribavirin are packaged together as a capsule and injection kit to treat chronic hepatitis C. These medications must be used together.
Interferon alfa-2b and ribavirin may also be used for other purposes not listed in this medication guide.
Use at least 2 effective forms of birth control while either sexual partner is using interferon alfa-2b and ribavirin. Keep using 2 forms of birth control for at least 6 months after treatment ends.
Before using interferon alfa-2b and ribavirin, tell your doctor about all of your medical conditions, especially kidney disease, liver problems other than hepatitis, heart disease or high blood pressure, a thyroid disorder, eye problems, HIV or AIDS, a blood cell disorder, an autoimmune disorder such as lupus or psoriasis, or a history of heart attack, stroke, organ transplant, depression, mental illness, drug or alcohol addiction, or suicidal thoughts or behaviors.
Also tell your doctor if you have ever used an interferon to treat hepatitis in the past and it did not work.
autoimmune hepatitis;
a hemoglobin blood cell disorder such as sickle-cell anemia or thalassemia;
if you are pregnant or breast-feeding; or
if you are a man and your female sexual partner is pregnant.
If you have any of these other conditions, you may need a dose adjustment or special tests to safely use interferon alfa-2b and ribavirin:
lung disease;
a thyroid disorder;
uncontrolled diabetes;
new or worsening problems with your eyes;
cancer;
HIV or AIDS;
high cholesterol or triglycerides;
heart disease or high blood pressure, history of heart attack, or stroke;
history of organ transplant;
any blood cell disorder causing bleeding episodes, infections, or fever-related illness;
an autoimmune disorder such as rheumatoid arthritis, systemic lupus erythematosus (SLE), or psoriasis;
a history of drug or alcohol addiction, depression, anxiety, or suicidal thoughts or behaviors; or
if you have ever used an interferon to treat hepatitis in the past and it did not work.
If you are a woman, do not use interferon alfa-2b and ribavirin if you are pregnant.
If you are a man, do not use interferon alfa-2b and ribavirin if your female sexual partner is pregnant. An unborn baby could also be harmed if a man fathers the child while he is taking ribavirin.
Use at least 2 effective forms of birth control while either sexual partner is using interferon alfa-2b and ribavirin. Keep using 2 forms of birth control for at least 6 months after treatment ends.
Tell your doctor right away if a pregnancy occurs while either the mother or the father is using interferon alfa-2b and ribavirin.
The powder form of interferon alfa-2b contains albumin, but the solution (liquid) form does not. Albumin comes from human plasma (part of the blood) and may contain viruses and other infectious agents that can cause disease. Although donated human plasma is screened, tested, and treated to reduce the risk of it containing anything that could cause disease, there is still a small possibility it could transmit disease. Talk with your doctor about the risks and benefits of using this medication.
Interferon alfa-2b is given as an injection under the skin. Your doctor, nurse, or other healthcare provider will give you this injection. You may be shown how to inject your medicine at home. Do not self-inject this medicine if you do not fully understand how to give the injection and properly dispose of used needles and syringes.
Use a different place on your arm, stomach, or thigh each time you give yourself an injection. Your care provider will show you the places on your body where you can safely inject the medication. Do not inject into the same place two times in a row.
Use each disposable needle only one time. Throw away used needles in a puncture-proof container (ask your pharmacist where you can get one and how to dispose of it). Keep this container out of the reach of children and pets.
The interferon alfa-2b injection is usually given 3 times per week. The ribavirin capsule is usually taken twice daily. You may take the capsules with or without food but take them the same way each time. Follow your doctor's instructions. Your doctor may occasionally change your dose to make sure you get the best results from this medication.
Your ribavirin dose needs may change if you gain weight. Tell your doctor if your weight increases to 165 pounds or above.
To be sure this medication is helping your condition and not causing harmful effects, your blood may need to be tested on a regular basis. You may also need regular eye exams. Do not miss any scheduled appointments.
Use the medicine as soon as you remember the missed dose, then go back to your regular schedule on the day your next dose is due. If you are more than 2 days late in using your injection, call your doctor for instructions. Do not use extra medicine to make up a missed dose.
Treatment with this medication does not prevent spread of the hepatitis virus to other people. Follow your doctor's instructions about how to prevent passing the disease to another person.
pale or yellowed skin, dark colored urine;
fever, chills, body aches, flu symptoms, easy bruising or bleeding, unusual weakness;
confusion, severe depression or anxiety, aggression, thoughts of hurting yourself or others;
vision problems;
high fever with severe stomach pain and bloody diarrhea.
cough, stabbing chest pain, feeling short of breath, uneven heartbeats;
severe pain in your upper stomach spreading to your back, nausea and vomiting, fast heart rate; or
worsening psoriasis or other autoimmune disorder.
Less serious side effects may include:
dizziness, tired feeling, headache, joint or muscle pain;
mild nausea, loss of appetite, weight loss;
sleep problems (insomnia);
feeling mildly anxious, depressed, or irritable; or
pain, redness, swelling, or irritation where the medicine was injected.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Tell your doctor about all other medications you use, especially HIV or AIDS medications such as :
abacavir (Ziagen);
didanosine (Videx);
efavirenz (Sustiva, Atripla);
emtricitabine (Emtriva);
etravine (Intelence);
lamivudine (Epivir, Epzicom, Combivir, Trizivir);
stavudine (Zerit);
tenofovir (Truvada, Viread); or
zidovudine (Retrovir).
See also: Rebetron side effects (in more detail)
In the US, Demser (metyrosine systemic) is a member of the drug class miscellaneous cardiovascular agents and is used to treat Pheochromocytoma.
US matches:
Metirosine is reported as an ingredient of Demser in the following countries:
International Drug Name Search
Celecoxib MK may be available in the countries listed below.
Celecoxib is reported as an ingredient of Celecoxib MK in the following countries:
International Drug Name Search
Gluicon may be available in the countries listed below.
Glibenclamide is reported as an ingredient of Gluicon in the following countries:
International Drug Name Search
Osiren may be available in the countries listed below.
Omeprazole is reported as an ingredient of Osiren in the following countries:
Spironolactone is reported as an ingredient of Osiren in the following countries:
International Drug Name Search
